

Esther Conde

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2832634/publications.pdf>

Version: 2024-02-01

13
papers

455
citations

1040056

9
h-index

1058476

14
g-index

14
all docs

14
docs citations

14
times ranked

761
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Context of the EGFR Mutations: Evidence for the Activation of mTOR/S6K Signaling. <i>Clinical Cancer Research</i> , 2006, 12, 710-717.	7.0	116
2	Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients. <i>Clinical Chemistry</i> , 2017, 63, 751-760.	3.2	62
3	Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry. <i>PLoS ONE</i> , 2014, 9, e107200.	2.5	58
4	The Use of P63 Immunohistochemistry for the Identification of Squamous Cell Carcinoma of the Lung. <i>PLoS ONE</i> , 2010, 5, e12209.	2.5	51
5	Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2120-2132.	1.1	48
6	Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 707-713.	3.1	43
7	Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing. <i>Journal of Clinical Pathology</i> , 2022, 75, 145-153.	2.0	26
8	Aligning digital CD8 ⁺ scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma. <i>Histopathology</i> , 2018, 72, 270-284.	2.9	17
9	Screening for ROS1 fusions in patients with advanced non-small cell lung carcinomas using the VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 437-444.	3.1	10
10	Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges. <i>Future Oncology</i> , 2021, 17, 4011-4025.	2.4	10
11	The anaplastic lymphoma kinase testing conundrum. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 161-163.	3.1	7
12	Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1500.	2.4	3
13	Clinical and economic impact of "ROS1-testing" strategy compared to a "no-ROS1-testing" strategy in advanced NSCLC in Spain. <i>BMC Cancer</i> , 2022, 22, 292.	2.6	2